Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 7/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5791728 | 0.91 | SMN1; SMN2 (0.49) | TGFBR1SLC2A1KDM4EGAAMAPKAPK2 | |
| SCHEMBL5788058 | 0.90 | TGFBR1 (0.57) | TGFBR1SLC2A1KDM4EGAAMAPKAPK2 | |
| SCHEMBL5791430 | 0.88 | SLC2A1 (0.50) | TGFBR1SLC2A1KDM4E | |
| SCHEMBL5787031 | 0.88 | GAA (0.48) | TGFBR1KDM4EGAAKDRMAPK14 | |
| SCHEMBL5789274 | 0.87 | TGFBR1 (0.46) | TGFBR1GAAMAPKAPK2KDRMAPK14 | |
| SCHEMBL5787871 | 0.83 | TGFBR1 (0.50) | TGFBR1KDRMAPK14 | |
| SCHEMBL6365567 | 0.82 | SLC2A1 (0.50) | TGFBR1SLC2A1KDM4EGAAMAPKAPK2 | |
| SCHEMBL5792573 | 0.81 | TGFBR1 (0.45) | TGFBR1KDRMAPK14 | |
| SCHEMBL5789474 | 0.81 | CDK4 (0.46) | TGFBR1GAAKDRMAPK14SMN1; SMN2 | |
| SCHEMBL5790400 | 0.80 | SLC2A1 (0.46) | TGFBR1SLC2A1KDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543003-B1 | IMIDAZO¬1,2-A|PYRIDINES | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | claimed |
| US-20050234029-A1 | Compounds | DODIC NERINA | 2005-10-20 | — | — | US | claimed |
| EP-1543003-A2 | IMIDAZO[1,2-A]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004013138-A2 | IMIDAZO`1,2-A!PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | claimed |
| EP-1543003-B1 | IMIDAZO¬1,2-A|PYRIDINES | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | DODIC NERINA | 2005-11-03 | — | — | US | disclosed |
| US-20050234029-A1 | Compounds | DODIC NERINA | 2005-10-20 | — | — | US | disclosed |
| EP-1543003-A2 | IMIDAZO[1,2-A]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004013138-A2 | IMIDAZO`1,2-A!PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | SMAD2, SMAD3, ALK | TGFBR1 7/4885SLC2A1 3514/4885KDM4E 514/4885 |
| US-20050234029-A1 | Compounds | SMAD3, SMAD2, ACVR1 | TGFBR1 4/4885SLC2A1 3838/4885KDM4E 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.